Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Gastric Bypass, Sleeve Gastrectomy, and Usual Care

OBJECTIVE
To determine which one of the two most common metabolic surgical procedures is associated with greater reduction in risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and obesity.

RESEARCH DESIGN AND METHODS
A total of 13,490 patients including 1,362 Roux-en-Y gastric bypass (RYGB), 693 sleeve gastrectomy (SG), and 11,435 matched nonsurgical patients with T2DM and obesity who received their care at the Cleveland Clinic (1998–2017) were analyzed, with follow-up through December 2018. With multivariable Cox regression analysis we estimated time to incident extended MACE, defined as first occurrence of coronary artery events, cerebrovascular events, heart failure, nephropathy, atrial fibrillation, and all-cause mortality.

RESULTS
The cumulative incidence of the primary end point at 5 years was 13.7% (95% CI 11.4–15.9) in the RYGB groups and 24.7% (95% CI 19.0–30.0) in the SG group, with an adjusted hazard ratio (HR) of 0.77 (95% CI 0.60–0.98, \( P = 0.04 \)). Of the six individual end points, RYGB was associated with a significantly lower cumulative incidence of nephropathy at 5 years compared with SG (2.8% vs. 8.3%, respectively; HR 0.47 [95% CI 0.28–0.79], \( P = 0.005 \)). Furthermore, RYGB was associated with a greater reduction in body weight, glycated hemoglobin, and use of medications to treat diabetes and cardiovascular diseases. Five years after RYGB, patients required more upper endoscopy (45.8% vs. 35.6%, \( P < 0.001 \)) and abdominal surgical procedures (10.8% vs. 5.4%, \( P = 0.001 \)) compared with SG.

CONCLUSIONS
In patients with obesity and T2DM, RYGB may be associated with greater weight loss, better diabetes control, and lower risk of MACE and nephropathy compared with SG.

More than 10 small randomized clinical trials (RCTs) have shown that metabolic surgery is superior to usual medical therapy for diabetes control and modifying cardiometabolic risk factors in patients with type 2 diabetes mellitus (T2DM) and...
obesity (1–5). Furthermore, >30 large comparative cohort studies have consistently reported reduction in risk of mortality after metabolic surgery (6–9). The majority of these RCTs and large observational studies have only examined the favorable effects of Roux-en-Y gastric bypass (RYGB). Currently, sleeve gastrectomy (SG), a relatively new procedure, is the most commonly performed metabolic surgical procedure worldwide (10,11). However, long-term data on efficacy of SG for macro- and microvascular complications of T2DM and mortality are limited.

Guiding patients toward the most appropriate metabolic surgical procedure for treatment of chronic diseases of obesity, T2DM, and their adverse events is crucial for improving outcomes. The surgical risk, impact of each procedure on body weight and comorbidities, coexistence of other medical and mental conditions, and patient behavioral factors, values, and goals are important considerations in choosing the most appropriate metabolic surgical procedure (12,13). One factor that may help in decision-making would be understanding the differential impact of each surgical procedure on the risk of major adverse cardiovascular events (MACE) and mortality. This important consideration has not been studied yet.

RESEARCH DESIGN AND METHODS

This is a secondary analysis of a matched-cohort study that originally reported association of metabolic surgery with lower risk of MACE in adult patients with obesity and T2DM (6). The main aim of the current study is to determine which metabolic surgical procedure (RYGB vs. SG) is associated with greater risk reduction in development of MACE. In addition, since there are limited data on the effects of SG on cardiovascular health, the second aim of this study is to examine the association of each metabolic surgical procedure separately with risk of MACE and mortality.

A retrospective observational study on patients who received treatment within the Cleveland Clinic Health System between 1 January 1998 and 31 December 2017 with follow-up through 31 December 2018 was performed. The Cleveland Clinic’s institutional review board approved the study as minimal risk research using data collected for routine clinical practice for which the requirement for informed consent was waived.

Details of the study protocol, enrollment criteria, construction of study cohorts, and statistical analysis have previously been published (6). The ICD-9, ICD-10, and Current Procedural Terminology (CPT) procedure codes that were used to extract data from the electronic health records (EHR) are summarized in Supplementary Tables 1 and 2.

Study Cohorts

A total of 2,287 adult patients with T2DM and BMI ≥30 kg/m² who underwent metabolic surgery and did not have a history of solid organ transplant, severe heart failure, or active cancer were identified. Among the 2,287 surgical patients of the original cohort, 1,362 RYGB and 693 SG cases are included in the current analysis. Patients who underwent adjustable gastric banding (n = 109), duodenal switch (n = 5), or conversion of primary SG and RYGB to other procedures (n = 118) were not included.

Enrollment criteria were implemented for identification of the nonsurgical patients who received usual care for T2DM and obesity. Each surgical patient was matched with a propensity score to five nonsurgical patients based on the index date, age at index date, sex, BMI at index date, location (Ohio vs. Florida), insulin use, and presence of diabetes end-organ complications (composite of coronary artery disease, heart failure, cerebrovascular disease, peripheral vascular disease, neuropathy, nephropathy, or requiring dialysis), resulting in 11,435 nonsurgical patients (6).

End Points

As described in the original study (6), the primary end point was the incidence of extended MACE, defined as first occurrence of any of six outcomes including all-cause mortality, coronary artery events (unstable angina, myocardial infarction, or coronary intervention/surgery), cerebrovascular events (ischemic stroke, hemorrhagic stroke, or carotid intervention/surgery), heart failure (diastolic and systolic), atrial fibrillation, and nephropathy (at least two measures of estimated glomerular filtration rate [eGFR] < 60 mL/min), with the first occurrence after the index date recorded as the event date (see Supplementary Table 1 for definitions and codes). A secondary composite end point included three-component MACE (all-cause mortality, myocardial infarction, and ischemic stroke).

All patients were included in the assessment of the composite primary and secondary end points. However, the conditions or events that a patient had at baseline were omitted from the count toward the composite end points in follow-up. For example, in a patient with history of ischemic stroke before the index date, having a code for stroke after the index date was not considered an event for composite end points. However, development of myocardial infarction in this patient after the index date would count toward the composite end points (6).

Other secondary end points included the six individual components of the primary end point including coronary artery events, cerebrovascular events, heart failure, atrial fibrillation, nephropathy, and all-cause mortality. Death information was obtained from a combination of local EHR, Social Security, and state death indices. For assessment of individual secondary end points, patients who already had these conditions prior to the index date were eliminated from subsequent risk evaluation only for that specific outcome.

Other Outcomes

Weight, glycated hemoglobin (HbA1c), and dates of prescription orders for diabetes and cardiovascular drugs were collected from the EHR for comparison of groups. Data on nutritional, endoscopic, radiologic, and surgical interventions until last follow-up were also compared between surgical procedures to serve as surrogates of surgical adverse events.

Statistical Analysis

Baseline data are expressed as median (interquartile range [IQR]) and number (%). Doubly robust estimation combining the propensity score and outcome regression was used to compare the outcomes between three study groups head-to-head.

Cause-specific event rates per 100 patient-years of follow-up starting from
the index date were estimated for each outcome within each study group. Cumulative incidence estimates (Kaplan-Meier method) 5 years after the index date with 95% CIs for each outcome were calculated.

Fully adjusted Cox proportional hazards regression models were generated for two composite and six individual study outcomes. Regression analyses were performed for all of the factors used in the matching process as well as a larger range of potential confounding variables (all variables in Table 1). Therefore, any imbalances in the observed potential confounders that remained after the matching process were controlled for by the statistical analysis. The proportional hazards assumptions for the treatment variable were tested based on weighted residuals.

To address missing values, within each outcome data set, we imputed missing values at baseline (Table 1) with multiple imputation by chained equations (MICE) to create five imputed data sets. Predictive mean matching, logistic regression, and polytomous logistic regression were used for numeric, binary, and categorical variables, respectively. Imputation-corrected SEs of model estimates and contrasts were obtained with Rubin’s formula (6, 14).

The Wald test was used for comparing mean changes in weight loss and HbA1c, two-sample proportions test for comparing proportions of patients on diabetes and cardiovascular medications, and log-rank test for comparing interventions between the study groups at 5 years of follow-up.

A significance level of 0.05 for two-sided comparisons was considered statistically significant, and 95% CIs were reported where applicable. Because of the potential for a type 1 error due to multiple comparisons, findings should be interpreted as exploratory. All analysis was done in the R statistical programming language (version 3.5.0).

RESULTS
A total of 13,490 patients including 1,362 RYGB, 693 SG, and 11,435 matched nonsurgical patients were included in the analysis. The median BMI of RYGB, SG, and control group was 45.3, 44.7, and 42.6 kg/m², respectively. In total, 4.3% of patients had a BMI between 30 and 34.9 kg/m².

The distribution of 37 baseline covariates was well balanced across matching among the RYGB, SG, and nonsurgical patient study groups (Table 1) including median HbA1c level (7.1% vs. 7.0% vs. 7.1%) and eGFR (91.3 vs. 90.4 vs. 91.9 mL/min) and percentage taking insulin (33.7% vs. 34.2% vs. 33.3%), cholesterol-lowering medications (52.6% vs. 51.5% vs. 52.5%), and renin-angiotensin system inhibitors (60.6% vs. 61% vs. 62.1%), respectively. Composed of RYGB patients, SG patients were older (54.6 vs. 51.2 years) and had higher rates of some comorbidities at baseline including heart failure (14.3% vs. 7.7%), history of myocardial infarction (3.3% vs. 1.9%), history of atrial fibrillation (9.1% vs. 5.2%), chronic obstructive pulmonary disease (11.1% vs. 8.4%), and nephropathy (9.8% vs. 6.9%). Conversely, the frequency of smoking (8.9% vs. 4.8%) and BMI ≥40 kg/m² (77.5% vs. 71.7%) was higher among patients receiving RYGB compared with SG. The median follow-up time for RYGB, SG, and nonsurgical patients was 4.0 years (IQR 1.3–7.0), 2.0 years (IQR 0.7–4.1), and 4.0 years (IQR 2.1–6.1), respectively.

Primary Composite End Point
The cumulative incidence of the primary end point at 5 years was 13.7% (95% CI 11.4–15.9) in the RYGB group and 24.7% (95% CI 19.0–30.0) in the SG group, with an adjusted hazard ratio (HR) of 0.77 (95% CI 0.60–0.98, P = 0.035) (Fig. 1A and Table 2). The cumulative incidence of the primary end point at 5 years was 30.4% (95% CI 29.4–31.5) in the nonsurgical group. Both metabolic surgical procedures were associated with a significantly lower cumulative incidence of the primary end point at 5 years compared with usual care: HR 0.53 (95% CI 0.46–0.61, P < 0.001) after RYGB and HR 0.69 (95% CI 0.56–0.85, P < 0.001) after SG (Fig. 1A and Table 2).

Secondary Composite End Point
The cumulative incidence of three-component MACE at 5 years was 15.5% (95% CI 14.7–16.4) in the nonsurgical group. Both metabolic surgical procedures were associated with significantly lower cumulative incidence of three-component MACE at 5 years in comparison with usual care: HR 0.53 (95% CI 0.43–0.65, P < 0.001) after RYGB and HR 0.65 (95% CI 0.48–0.88, P = 0.006) after SG (Fig. 1B and Table 2).

Secondary Individual End Points
RYGB was associated with a significantly lower cumulative incidence of nephropathy at 5 years compared with SG (2.8% vs. 8.3%, respectively) (HR 0.47 [95% CI 0.28–0.79, P = 0.005]). Although the 5-year cumulative incidences of the other five individual end points were lower after RYGB, the fully adjusted HRs were not significantly different in comparison of RYGB and SG (Fig. 2, Table 2, and Supplementary Table 3).

Compared with usual care, RYGB was associated with a significantly lower incidence of five out of six individual end points and SG was associated with a significantly lower incidence of three out of six individual end points. The incidence for these end points and adjusted HRs are reported in Table 2 and Supplementary Table 3. The proportional hazards assumption was satisfied for the primary and secondary composite outcomes and individual outcomes (see Supplementary Table 4 for P values testing the proportional hazards assumption).

Change in Status of Obesity, Diabetes, and Medications
Both metabolic surgical procedures were associated with a significant reduction in weight and HbA1c level in comparisons with the control group (P < 0.001 for all four comparisons at 5 years). Patients who underwent RYGB on average had 9.7%-points greater weight loss (95% CI 9.3–10.1, P < 0.001) and a 0.31% lower HbA1c level (95% CI 0.16–0.47, P < 0.001) at 5 years compared with SG patients (Fig. 3 and Supplementary Table 5).

Patients after RYGB and SG required significantly less diabetes and cardiovascular medication compared with those who received usual care. Furthermore, use of noninsulin diabetes medications, renin-angiotensin system blockers, lipid-lowering therapies, and aspirin was significantly lower after the
Table 1—Characteristics of patients at the index date

| Baseline variable | RYGB (N = 1,362) | SG (N = 693) | Nonsurgical control (N = 11,435) |
|-------------------|------------------|-------------|---------------------------------|
| **Demographic data** |                  |             |                                 |
| **Index year**     | 2012 (2010, 2014) | 2014 (2012, 2016) | 2013 (2011, 2015) |
| **Sex**            |                  |             |                                 |
| Female             | 908 (66.7)       | 439 (63.3)  | 7,339 (64.2)                    |
| Male               | 454 (33.3)       | 254 (36.7)  | 4,096 (35.8)                    |
| **Age (years)**    | 51.2 (43.1, 58.4) | 54.6 (44.6, 62.8) | 54.8 (46.2, 62.5) |
| **BMI (kg/m²)**    | 45.3 (40.7, 51.5) | 44.7 (39.3, 52.5) | 42.6 (39.4, 47.2) |
| BMI category (kg/m²) |                  |             |                                 |
| 30–34.9 | 58 (4.3)         | 30 (4.3)    | 495 (4.3)                       |
| 35–39.9 | 249 (18.3)       | 166 (24)    | 2,595 (22.7)                    |
| ≥40     | 1,055 (77.5)     | 497 (71.7)  | 8,345 (73)                      |
| **Weight (kg)**    | 126.8 (112, 147) | 125.6 (108.4, 149.4) | 120.2 (106.8, 136.5) |
| **Race**           |                  |             |                                 |
| White             | 1,066 (78.3)     | 492 (71)    | 7,994 (69.9)                    |
| Black             | 239 (17.5)       | 156 (22.5)  | 2,804 (24.5)                    |
| Other             | 23 (1.7)         | 27 (3.9)    | 234 (2)                         |
| Missing           | 34 (2.5)         | 18 (2.6)    | 403 (3.5)                       |
| **Annual zip code income ($)** | 49,664 (39,730, 61,278) | 50,925 (41,013, 63,445) | 48,732 (36,951, 61,512) |
| Missing           | 29 (2.1)         | 34 (4.9)    | 125 (1.1)                       |
| **Smoking status** |                  |             |                                 |
| Never             | 724 (53.2)       | 383 (55.3)  | 5,615 (49.1)                    |
| Former            | 480 (35.2)       | 261 (37.7)  | 4,012 (35.1)                    |
| Current           | 121 (8.9)        | 33 (4.8)    | 1,607 (14.1)                    |
| Missing           | 37 (2.7)         | 16 (2.3)    | 201 (1.8)                       |
| **Location**      |                  |             |                                 |
| Ohio              | 1,231 (90.4)     | 390 (56.3)  | 9,834 (86)                      |
| Florida           | 131 (9.6)        | 303 (43.7)  | 1,601 (14)                      |
| **Medical history** |                  |             |                                 |
| Hypertension      | 1,165 (85.5)     | 587 (84.7)  | 8,565 (74.9)                    |
| Dyslipidemia      | 1,042 (76.5)     | 483 (69.7)  | 7,457 (65.2)                    |
| Peripheral neuropathy | 139 (10.2) | 84 (12.1) | 1,203 (10.5) |
| Heart failure     | 105 (7.7)        | 99 (14.3)   | 1,342 (11.7)                    |
| Coronary artery disease | 129 (9.5) | 81 (11.7) | 1,104 (9.7) |
| COPD              | 114 (8.4)        | 77 (11.1)   | 1,188 (10.4)                    |
| Nephropathy       | 94 (6.9)         | 68 (9.8)    | 1,219 (10.7)                    |
| Atrial fibrillation | 71 (5.2) | 63 (9.1) | 701 (6.1) |
| Peripheral arterial disease | 66 (4.8) | 47 (6.8) | 755 (6.6) |
| Myocardial infarction | 26 (1.9) | 23 (3.3) | 211 (1.8) |
| Cerebrovascular disease | 18 (1.3) | 19 (2.7) | 358 (3.1) |
| Ischemic stroke    | 17 (1.2)         | 13 (1.9)    | 298 (2.6)                       |
| Dialysis          | 5 (0.4)          | 8 (1.2)     | 78 (0.7)                        |
| **Clinical and laboratory data** |                  |             |                                 |
| HbA₁c % | 7.1 (6.3, 8.4) | 7 (6.4, 8) | 7.1 (6.4, 8.4) |
| mmol/mol | 54 (45, 68) | 53 (46, 64) | 54 (46, 68) |
| Missing | 88 (6.5) | 50 (7.2) | 1,288 (11.3) |
| Systolic blood pressure (mmHg) | 136.7 (126, 147.3) | 141.3 (130.8, 151.2) | 130.2 (121, 142) |
| Missing | 0 (0) | 0 (0) | 54 (0.5) |
| Diastolic blood pressure (mmHg) | 72 (65.5, 79.7) | 71.2 (65, 78) | 78 (70, 84) |
| Missing | 0 (0) | 0 (0) | 54 (0.5) |
| eGFR (mL/min)⁴ | 91.3 (74, 107.9) | 90.4 (69.8, 111.5) | 91.9 (72.5, 111.9) |
| Missing | 0 (0) | 1 (0.1) | 432 (3.8) |
| HDL (mg/dL) | 43 (36, 51) | 45 (38, 51.5) | 43 (36, 51) |
| Missing | 378 (27.8) | 346 (49.9) | 3,512 (30.7) |
| LDL (mg/dL) | 93 (72, 116) | 91 (71, 116) | 93 (72, 118) |
| Missing | 121 (8.9) | 56 (8.1) | 2,947 (25.8) |
| Triglycerides (mg/dL) | 150 (104, 216.5) | 139 (96, 197.5) | 146 (103, 208) |
| Missing | 87 (6.4) | 46 (6.6) | 1,816 (15.9) |
| UACR (mg/g) | 14 (6, 39.8) | 14.2 (4.8, 39.8) | 14 (5.4) |
| Missing | 532 (39.1) | 353 (50.9) | 4,224 (36.9) |

Continued on p. 2556
RYGB compared with SG (Fig. 4 and Supplementary Table 6).

Adverse Events After Metabolic Surgery
The cumulative incidence of different interventions after RYGB and SG is shown in Fig. 5 and reported in Supplementary Table 7. More patients 5 years after RYGB required upper endoscopy (45.8% vs. 35.6%, \( P < 0.001 \)) and abdominal surgical procedures (10.8% vs. 5.4%, \( P < 0.001 \)) compared with patients after SG.

**CONCLUSIONS**

Findings of this study indicate that RYGB and SG were separately associated with a significant reduction in risk of MACE and all-cause mortality compared with usual care among patients with T2DM and a BMI ≥ 30 kg/m². Furthermore, during 5 years of follow-up, RYGB compared with SG was associated with a greater reduction in body weight, HbA₁c, use of medications to treat diabetes and cardiovascular diseases, and risk of six-component MACE. Among the individual components of MACE in this study, protective effects of RYGB versus SG were more prominent for risk of nephropathy than other end points. Nonetheless, more patients required endoscopic and abdominal surgical procedures after RYGB compared with SG.

In current practice, RYGB and SG account for >95% of metabolic surgical procedures performed in patients with T2DM (10,11). Despite the well-known metabolic effects of RYGB, SG has become a more popular procedure worldwide in the last several years, largely because of the relative ease of performing the procedure and fewer short- and long-term complications after SG (12,15–17). To date, there are only a few RCTs directly comparing long-term metabolic effects of RYGB with SG (3,18,19). These small trials were not primarily designed and adequately powered to specifically compare the impact of RYGB and SG on T2DM-related end

---

**Table 1—Continued**

| Baseline variable | RYGB (N = 1,362) | SG (N = 693) | Nonsurgical control (N = 11,435) |
|-------------------|-----------------|-------------|---------------------------------|
| **Medication history** | | | |
| Noninsulin diabetes medication | 1,139 (83.6) | 553 (79.8) | 9,253 (80.9) |
| 0 | 223 (16.4) | 140 (20.2) | 2,182 (19.1) |
| 1 | 628 (46.1) | 351 (50.6) | 5,218 (45.6) |
| 2 | 362 (26.6) | 148 (21.4) | 2,929 (25.6) |
| 3+ | 149 (10.9) | 54 (7.8) | 1,106 (9.7) |
| Insulin | 459 (33.7) | 237 (34.2) | 3,806 (33.3) |
| Lipid-lowering medications | 716 (52.6) | 357 (51.5) | 5,998 (52.5) |
| Renin-angiotensin system inhibitorsb | 825 (60.6) | 423 (61) | 7,102 (62.1) |
| Other antihypertensive medications | 973 (71.4) | 501 (72.3) | 8,066 (70.5) |
| Aspirin | 451 (33.1) | 216 (31.2) | 4,627 (40.5) |
| Warfarin | 99 (7.3) | 66 (9.5) | 943 (8.2) |

Data are \( n (\%) \) or median (IQR). COPD, chronic obstructive pulmonary disease; UACR, urinary albumin-to-creatinine ratio. \( ^{a} \) eGFR was estimated using the MDRD study equation. \( ^{b} \) Including ACE inhibitors and angiotensin-receptor blockers.

---

**Figure 1**—Five-year cumulative incidence estimates (Kaplan-Meier) for two composite end points. The primary end point was the incidence of extended MACE (composite of six outcomes), defined as first occurrence of coronary artery events, cerebrovascular events, heart failure, atrial fibrillation, nephropathy, and all-cause mortality, with the first occurrence after the index date recorded as the event date. The secondary composite end points included three-component MACE (all-cause mortality, myocardial infarction, and ischemic stroke), with the first occurrence after the index date recorded as the event date.
Table 2—Cumulative incidence estimates (%) and fully adjusted HRs from Cox models for each outcome stratified by treatment

| Outcome                      | Cumulative incidence at 5 years, % (95% CI) | RYGB | SG | Nonsurgical control | HR (95% CI) | P     |
|------------------------------|---------------------------------------------|------|----|---------------------|------------|-------|
| Primary                      |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 13.7 (11.4–15.9)                            | 24.7 (19.0–30.0) | 30.4 (29.4–31.5) | 0.77 (0.60–0.98) | 0.035 |
| RYGB vs. control             |                                             | 0.53 (0.46–0.61) | 0.001 |
| SG vs. control               |                                             | 0.69 (0.56–0.85) | <0.001 |
| Secondary composite         |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 6.4 (4.8–8.0)                               | 11.8 (7.6–15.8) | 15.5 (14.7–16.4) | 0.81 (0.57–1.16) | 0.258 |
| RYGB vs. control             |                                             | 0.53 (0.43–0.65) | <0.001 |
| SG vs. control               |                                             | 0.65 (0.48–0.88) | 0.006 |
| All-cause mortality          |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 3.9 (2.6–5.1)                               | 4.5 (2.0–6.9) | 10.1 (9.4–10.8) | 0.99 (0.60–1.66) | 0.983 |
| RYGB vs. control             |                                             | 0.51 (0.39–0.67) | <0.001 |
| SG vs. control               |                                             | 0.52 (0.33–0.81) | 0.004 |
| Heart failure                |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 2.9 (1.7–4.1)                               | 5.3 (1.8–8.7) | 10.7 (10.0–11.5) | 0.79 (0.45–1.39) | 0.416 |
| RYGB vs. control             |                                             | 0.32 (0.23–0.44) | <0.001 |
| SG vs. control               |                                             | 0.40 (0.25–0.66) | <0.001 |
| Coronary artery disease      |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 2.7 (1.5–3.8)                               | 7.1 (3.9–10.2) | 7.1 (6.4–7.7) | 0.63 (0.38–1.05) | 0.077 |
| RYGB vs. control             |                                             | 0.56 (0.41–0.77) | <0.001 |
| SG vs. control               |                                             | 0.89 (0.58–1.37) | 0.606 |
| Cerebrovascular disease      |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 1.6 (0.7–2.5)                               | 3.6 (0.9–6.2) | 3.3 (2.8–3.7) | 0.70 (0.34–1.45) | 0.340 |
| RYGB vs. control             |                                             | 0.59 (0.38–0.92) | 0.019 |
| SG vs. control               |                                             | 0.85 (0.46–1.56) | 0.593 |
| Nephropathy                  |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 2.8 (1.6–4.0)                               | 8.3 (4.1–12.3) | 9.1 (8.3–9.9) | 0.47 (0.28–0.79) | 0.005 |
| RYGB vs. control             |                                             | 0.32 (0.23–0.45) | <0.001 |
| SG vs. control               |                                             | 0.68 (0.45–1.05) | 0.081 |
| Atrial fibrillation          |                                             |      |    |                     |            |       |
| RYGB vs. SG                  | 4.2 (2.9–5.6)                               | 6.0 (2.5–9.4) | 7.9 (7.3–8.6) | 1.30 (0.76–2.22) | 0.340 |
| RYGB vs. control             |                                             | 0.76 (0.57–1.00) | 0.054 |
| SG vs. control               |                                             | 0.58 (0.36–0.94) | 0.027 |

HRs (95% CIs) and P values from adjusted Cox models comparing the relative instantaneous risk of each outcome among the study groups. When P value is <0.05, the “left” group is at a lower instantaneous risk of the outcome than the “right” group when the HR is <1. We included all baseline variables in Table 1 to adjust for potential confounding.

In the current study, the greater and more sustained weight loss after RYGB compared with SG (10% difference in total weight loss at 5 years) could have meaningful physiologic effects. Similarly, in a recent retrospective observational cohort study from 41 health systems in the U.S. on nearly 5,000 patients, the average weight loss at 5 years was 71 lb (26% total body weight loss) after RYGB and 52 lb (19% total body weight loss) after SG (20). Although weight loss drives many of the metabolic improvements after bariatric surgery, the relative contribution of weight-independent mechanisms remains an area of active investigation. Current evidence suggests that RYGB may lead to greater weight-independent metabolic and neurohormonal
Figure 2—Five-year cumulative incidence estimates (Kaplan-Meier) for six individual end points. For each five individual outcomes (except all-cause mortality), any patient with a history of that outcome prior to the index date was eliminated from risk assessment only for that outcome.
benefits compared with SG (21,22). This constellation of favorable weight loss–dependent and weight-independent changes may explain better diabetes control, less medication use, and reduced risk of MACE after RYGB.

The combination of obesity, T2DM, and hypertension has a large negative impact on kidney integrity and function (23,24). Among the six individual secondary end points, RYGB was associated with 53% lower risk of nephropathy compared with SG. Although the exact explanation of this observation remains for future studies, this finding supports other evidence showing that the risk of nephropathy is extremely sensitive to weight changes and diabetes control (25–28). Despite no reduction in cardiovascular outcomes, findings of the Look AHEAD (Action for Health in Diabetes) randomized trial suggest that among patients with T2DM, intensive life modifications significantly decrease the risk of chronic kidney disease (26). Furthermore, in large clinical trials the impact of intensive glucose control has been more prominent on the risk of nephropathy than the risk of cardiovascular events (27,28). The relative contributions of weight loss, diabetes and blood pressure control, altered adipokine levels, decreased inflammation, and gut hormone signaling toward improving nephropathy risk and progression are yet to be elucidated (29–31). As shown in Table 2 and Fig. 2, we also observed some evidence of lower risk of coronary artery events favoring RYGB compared with SG (HR 0.63 [95% CI 0.38–1.05]), which did not reach conventional levels of statistical significance (P = 0.08). Both surgical groups had comparable effects for other secondary individual end points including all-cause mortality. Overall, there has been substantial evidence to support the improvement of cardiovascular risk after metabolic surgery. Because of the close association between diabetes and cardiovascular disease, it is also clear that greater metabolic improvements, particularly diabetes remission, lead to greater reduction in long-term cardiovascular risk (6–9).

The safety profile of metabolic surgery has remarkably improved in the last two decades (32–34). Consistent with prior studies (15–17,20), the current study showed fewer complications after SG compared with RYGB. The need for more reinterventions long-term after RYGB compared with SG has previously been documented and is primarily related to ulceration or stricture formation at the gastrojejunosotomy and bowel obstructions. Although development of new gastroesophageal reflux disease or worsening of existing gastroesophageal reflux is a well-known adverse effect of SG (35), in the current study, similar to findings of prior studies (15–17), we found a lower rate of upper endoscopy in follow-up after SG compared with RYGB. Shorter operative time, lack of a gastrointestinal anastomosis, maintaining nutritional flow through an intact pylorus and small intestine, and unaltered gut absorption may contribute to a better safety profile of SG (12,15–17,20). In the field of metabolic surgery, gastrointestinal bypass procedures are generally associated with more weight loss and greater metabolic benefits but at a cost of higher surgical and nutritional complications and reintervention rates (12,36,37). There also appears to be a dose-response relationship between the length of the intestinal bypass, particularly the biliopancreatic limb, and the magnitude and duration of metabolic improvement (38,39).

Several factors should be considered when the patient and medical team make a shared decision about the most appropriate metabolic surgical procedure (12). The current study shows that while both RYGB and SG are safe, effective, and durable operations, RYGB is associated with greater metabolic effects and greater reduction in risk of MACE and nephropathy. Overall, RYGB outperforms SG in achieving diabetes remission (40). Conversely, SG may be a better choice in patients with higher surgical risk, when there is limited intra-abdominal working space to perform more complex operations due to extreme obesity or complex abdominal wall hernias, in patients with certain small bowel diseases (e.g., Crohn disease, or history of multiple bowel resections), in solid organ transplant patients or in patients requiring psychotropic polypharmacy (because of possible lesser effect on absorption of medications), and in active smokers and patients dependent on chronic nonsteroidal anti-inflammatory drugs (to avoid risk of anastomotic ulceration of RYGB) (12,41). Notably, the recommended nutritional surveillance in short- and long-term follow-up after RYGB and SG is similar (42).

This study has several limitations. First, the study cohorts were derived from the original study, where investigators comprehensively
matched a surgical group with a nonsurgical group (6), which was not specifically designed to match and compare RYGB and SG subgroups. The propensity score matching was originally done to obtain a sample from a group of clinically valid comparators for the surgical patients—not to control for differences in every patient characteristic between RYGB and SG subgroups. The intention of the regression adjustment was to be the main method of actual statistical
Figure 5—Five-year cumulative incidence estimates (Kaplan-Meier) for interventions after RYGB and SG. More patients after RYGB than after SG required upper endoscopy (45.8% vs. 35.6%, \(P < 0.001\)) and abdominal surgical procedures (10.8% vs. 5.4%, \(P = 0.001\)). Cumulative incidences and statistical comparisons are reported in Supplementary Table 7. Abdominal surgical procedure does not include repair of abdominal wall hernia or cholecystectomy.
adjustment for comparison of three study groups in order to control any imbalances that remained after the matching process. Nonetheless, residual measured or unmeasured confounders could have influenced findings of this retrospective observational study. Second, the SG group has a relatively smaller sample size and shorter follow-up time compared with other groups. Nonetheless, those were adequate to provide enough power to show differential impact of surgical procedures (favoring RYGB) on the primary composite end point of study. If this study could not show any difference in the primary end point between two surgical procedures, one valid argument would be lack of enough power due to smaller sample size and shorter follow-up time of the SG group than of the RYGB group. More studies with larger sample size, longer follow-up time, and higher number of events are needed to assess whether RYGB and SG have significantly different rates of “individual” cardiovascular end points beyond six-component MACE and nephropathy. In the current study, the HR for five of six individual cardiovascular end points favored RYGB compared with SG, although the upper 95% CI was <1 only for the nephropathy outcome. Particularly, the adjusted HR of coronary artery events for RYGB versus SG was 0.63 (95% CI 0.38–1.05), which did not reach conventional levels of statistical significance ($P = 0.08$). Third, coding errors, misclassification, and misdiagnosis can occur in EHR-driven data. Fourth, the causes of death could not be determined. Fifth, to analyze the status of diabetes and cardiovascular medications, prescription orders for medications were assessed, which does not necessarily equate to actual medication use. Sixth, surgical adverse events that did not lead to intervention were not analyzed. Indications and diagnoses associated with interventions were not collected. Seventh, a small percentage of nonsurgical patients received newer diabetes medications including glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors that could be associated with significant cardiovascular benefits (6).

Although cardiovascular and survival benefits of RYGB have been reported, the current study is among the first in the literature to show lower risk of MACE and mortality after SG compared with usual care. The findings of this large retrospective study also provide evidence suggesting that RYGB in patients with obesity and T2DM may be associated with greater weight loss, better diabetes control, and lower risk of six-component MACE and nephropathy compared with SG. However, given the nature of the study, these data should be considered hypothesis generating and not conclusive.

Acknowledgments. The authors acknowledge Alex Milinovich and Jian Jin from Department of Quantitative Health Sciences, Cleveland Clinic, for creation of the study database and data collection. The authors also acknowledge Dr. David E. Arterburn from Kaiser Permanente Washington Health Research Institute, Seattle, WA, for critical review of manuscript. The individuals acknowledged above did not receive compensation for their role in the study.

Duality of Interest. A.A. reports receiving grants from Medtronic. P.R.S. reports receiving grants from Medtronic, Ethicon, and Pacira and receiving personal fees from Medtronic, Gl Dynamics, W. L. Gore & Associates, Becton Dickinson Surgical, and Global Academy for Medical Education. M.W.K. reports receiving grants from Medtronic and Novo Nordisk. S.E.N. reports receiving a grant from Medtronic for the current study and receiving research support from Amgen, AbbVie, AstraZeneca, Cerenis Therapeutics, Eli Lilly, ESPIRON Therapeutics, Novo Nordisk, The Medicines Company, Orexigen, Pfizer, and Takeda. S.A.B. reports receiving honoraria and consulting fees from Medtronic and Gl Windows. No other potential conflicts of interest relevant to this article were reported.

S.E.N. reports consulting for a number of pharmaceutical companies without financial compensation (all honoraria, consulting fees, or any other payments from any for-profit entity are paid directly to charity, so income is not received and there is not any tax deduction).

Author Contributions. All authors contributed to study concept and design. A.A., R.W., A.Z., C.T., and M.W.K. contributed to acquisition and analysis of data. A.Z. and C.T. contributed to statistical analysis. All authors contributed to interpretation of data. A.A. and S.A.B. contributed to drafting of the manuscript. All authors contributed to critical revision of the manuscript. A.A., K.E.W., M.W.K., and S.E.N. provided administrative, technical, or material support. A.A. and S.E.N. provided supervision. A.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Ikramuddin S, Korner J, Lee WJ, et al. Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study. JAMA 2018;319:266–278
2. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964–973
3. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641–651
4. Courcoulas AP, Gallagher JW, Neiberg RH, et al. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial. J Clin Endocrinol Metab 2020;105:866–876
5. Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 2016;59:945–953
6. Aminian A, Zajicek A, Arterburn DE, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 2019;322:1271–1282
7. Fisher DP, Johnson E, Hanese S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA 2018;320:1570–1582
8. Aminian A, Nissen SE. Success (but unfinished) story of metabolic surgery. Diabetes Care 2020;43:1175–1177
9. Aminian A, Aleassa EM, Bhatt DL, et al. Bariatric surgery is associated with a lower rate of death after myocardial infarction and stroke: a nationwide study. Diabetes Obes Metab 2019;21:2058–2067
10. Angriani L, Santonicola A, Lovino P, et al. IFSO worldwide survey 2016: primary, endoluminal, and revisional procedures. Obes Surg 2018;28:3783–3794
11. English WJ, DeMaria EJ, Hutter MM, et al. American Society for Metabolic and Bariatric Surgery 2018 estimate of metabolic and bariatric procedures performed in the United States. Surg Obes Relat Dis 2020;16:457–463
12. Aminian A. Bariatric procedure selection in patients with type 2 diabetes: choice between Roux-en-Y gastric bypass or sleeve gastrectomy. Surg Obes Relat Dis 2020;16:332–339
13. Hofsø D, Fatima F, Borgeraas H, et al. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:912–924
14. Rubin DB. Inference and missing data. Biometrika 1976;63:581–592
15. Lewis KH, Arterburn DE, Callaway K, et al. Risk of operative and nonoperative interventions up to 4 years after Roux-en-Y gastric bypass vs vertical sleeve gastrectomy in a nationwide US commercial insurance claims database. JAMA Netw Open 2019;2:e1917603
16. Li RA, Liu L, Arterburn D, et al. Five-year longitudinal cohort study of reinterventions after sleeve gastrectomy and Roux-en-Y gastric bypass. Ann Surg 2021;273:758–765
17. Courcoulas A, Coley RY, Clark JM, et al.; PCORnet Bariatric Study Collaborative. Interventions and operations 5 years after bariatric surgery in a cohort from the US Patient-Centered Clinical Research Network Bariatric Study. JAMA Surg 2020;155:194–204
18. Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg 2018;319:241–254
19. Peterli R, Wöllerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA 2018;319:255–265
20. Arterburn D, Wellman R, Emiliano A, et al.; PCORnet Bariatric Study Collaborative. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Ann Intern Med 2018;169:741–750
21. Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 2016;39:893–901
22. Chondronikola M, Harris LL, Klein S. Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass? J Intern Med 2016;280:476–486
23. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol 2019;15:34–48
24. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014;7:75–88
25. Cohen JB, Cohen DL. Cardiovascular and renal effects of weight reduction in obesity and the metabolic syndrome. Curr Hypertens Rep 2015;17:34
26. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2014;2:801–809
27. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
29. Cohen RV, Pereira TV, Aboud CM, et al. Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial. JAMA Surg 2020;155:e200420
30. Young L, Nor Hanipah Z, Brethauer SA, Schauer PR, Aminian A. Long-term impact of bariatric surgery in diabetic nephropathy. Surg Endosc 2019;33:1654–1660
31. Scheurlein KM, Probst P, Kopf S, Nawroth PP, Billeter AT, Müller-Stich BP. Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. Surg Obes Relat Dis 2019;15:1006–1020
32. Daigle CR, Brethauer SA, Tu C, et al. Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis 2018;14:652–657
33. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? Diabetes Obes Metab 2015;17:198–201
34. Sebastianelli L, Benoist M, Vanbiervliet G, et al. Systematic endoscopy 5 years after sleeve gastrectomy results in a high rate of Barrett’s esophagus: results of a multicenter study. Obes Surg 2019;29:1462–1469
35. Gu L, Huang X, Li S, et al. A meta-analysis of the medium- and long-term effects of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass. BMC Surg 2020;20:30
36. Yang P, Chen B, Xiang S, Lin XF, Luo F, Li W. Long-term outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass for morbid obesity: results from a meta-analysis of randomized controlled trials. Surg Obes Relat Dis 2019;15:546–555
37. Patrício BG, Morais T, Guimarães M, et al. Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. Int J Obes 2019;43:1009–1018
38. Zorrilla-Nunez LF, Campbell A, Giambartolomei G, Lo Menzo E, Szomstein S, Rosenthal RJ. The importance of the biliopancreatic limb length in gastric bypass: A systematic review. Surg Obes Relat Dis 2019;15:43–49
39. Aminian A, Brethauer SA, Andalib A, et al. Individualized Metabolic Surgery score: procedure selection based on diabetes severity. Ann Surg 2017;266:650–657
40. Rosenthal RJ, Diaz AA, Arvidsson D, et al.; International Sleeve Gastrectomy Expert Panel. International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis 2012;8:8–19
41. O’Kane M, Parretti HM, Pinkney J, et al. British Obesity and Metabolic Surgery Society Guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery-2020 update. Obes Rev 2020;21:e13087